Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy
Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, global, double-blind, randomized, placebo-controlled study of adjunctive
GNX treatment in children and adults with TSC-related epilepsy. The study consists of a
4-week prospective baseline phase, defined as the first 28 days following screening, followed
by a double-blind phase consisting of a 4-week titration period (with 2 additional weeks
allowed, if necessary, for tolerance) and a 12-week maintenance period.